Global Pediatric Vaccines Market Size study, by Vaccine Type (Monovalent and Multivalent), by Application (Pneumococcal Disease, Influenza, Measles, Mumps, and Rubella (MMR), and Other Applications), by Technology (Live Attenuated, Inactivated, Toxoid, Conjugate and Other Technologies) and Regional Forecasts 2022-2028

"Global Pediatric Vaccines Market is valued at approximately USD 47.8 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.3% over the forecast period 2022-2028. Pediatric Vaccines trigger the body’s immune system to produce the requisite antibodies to protect infants from various diseases such as polio, pneumonia, and influenza. These vaccines are necessary to develop resistance to infections caused by these pathogens. An increase in the pediatric population is driving the market growth. 

For instance, according to the World Bank, the birth rate, (per 1,000 people) increased from 17.888 in 2019 to 17.982 in 2020. Furthermore, the total market is also expected to be driven by the high prevalence of pediatric diseases such as pneumonia, asthma, chickenpox, and others. According to the World Health Organization, in 2019, pneumonia causes 14% of all deaths of children under 5 years old, killing 740 180 children. Also, increasing R&D in vaccines, government support to reduce burden of diseases, and developments in the route of vaccine administration are likely to increase the market growth during the forecast period. However, low accessibility of vaccines to remote areas and high cost of vaccines impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Pediatric Vaccines Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region across the world in terms of market share owing to the well-established healthcare infrastructure and wide commercial availability of vaccines. Whereas, Asia-Pacific is anticipated to exhibit the highest growth rate over the forecast period 2022-2028 due to favorable government initiatives regarding vaccine development and awareness and increasing number of diseases.

Major market players included in this report are:
GlaxoSmithKline Plc.
Merck & Co., Inc.
Pfizer Inc.
Sanofi S.A.
Panacea Biotec
Zydus Cadila
Emergent BioSolutions Inc.
Serum Institute of India Pvt. Ltd.
Bharat Biotech
Indian Immunologicals Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: 

By Vaccine Type:
Monovalent
Multivalent
By Application:
Pneumococcal Disease
Influenza
Measles, Mumps and Rubella (MMR)
Other Applications
By Technology:
Live Attenuated
Inactivated
Toxoid
Conjugate
Other Technologies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia 
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Pediatric Vaccines Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors